

NOV. 14. 2002 12:32PM

NO. 2614 P. 13

EXHIBIT A

Dear Colleague

You have requested release date information for EMBL entry: X96526

The date given in the first DT line of this entry is the date the entry first became available for public disclosure.

Example:

DT dd-month-year (Rel. nn, Created)

The date in the Submission Reference RL line

Example:

RL Submitted (dd-month-year) to the EMBL/GenBank/DBJ databases.
is the date that EMBL received the submission from the submitter.

DISCLAIMER: PLEASE NOTE

No guarantee is given that release date given in the entry is accurate. The actual release date will depend on the availability of network services.

No guarantee is given that the entry is complete and accurate. In particular the sequence data of the entry may not conform to the sequence data of the original publication where the sequence was first disclosed to the public.

I enclose a copy of the entry.

ID HIV1686EN standard; DNA; VRL; 2640 BP.
XX
AC X96526;
XX
SV X96526.1
XX
DT 28-AUG-1996 (Rel. 49, Created)
DT 02-MAR-1999 (Rel. 59, Last updated, Version 8)
XX
DE Human immunodeficiency virus type 1 env gene, strain VI686
XX
KW env gene; gp 120; gp160; gp41.
XX
OS Human immunodeficiency virus type 1

OC Viruses; Retrovird viruses; Retroviridae; Lentivirus;
 OC Primate lentivirus group.
 XX
 RN [1]
 RP 1-2640
 RA Janssens W.;
 RT ;
 RL Submitted (28-FEB-1996) to the EMBL/GenBank/DDBJ databases.
 RL W. Janssens, Institute of Tropical Medicine, Nationalestraat 155, 2000
 RL Antwerpen, BELGIUM
 XX
 RN [2]
 RA Janssens W., Heyndrickx L., Van der Auwera G., Nkengasong J., Beirnaert
 E.,
 RA Vereecken K., Coppens S., Willems B., Franssen K., Peeters M., Ndumbe P.,
 RA Delaporte E., Van der Groen G.;
 RT "Interpatient genetic variability of HIV-1 group O";
 RL AIDS 13:41-48(1999).
 XX
 RN [3]
 RP 1-2640
 RA Delaporte E., Janssens W., Peeters M., Buve A., Dibanga G., Perret J.L.,
 RA Ditsambou V., Georges Courbot M.C., Georges A., Bourgeois A., Samb B.,
 RA Henzel D., Heyndrickx L., Franssen K., Van der Groen G., Larouz B.,
 RA Mbe J.R.;
 RT "Epidemiological and Molecular characteristics of HIV infection in Gabon
 RT (1986 - 1994).";
 RL AIDS 10:903-910(1996).
 XX
 DR SPTREMBL; Q9WIU9; Q9WIU9.
 XX
 FH Key Location/Qualifiers
 FH
 FT source 1..2640
 FT /db_xref="taxon:11676"
 FT /note="isolated from lymphocytes"
 FT /proviral
 FT /organism="Human immunodeficiency virus type 1"
 FT /strain="VI696"
 FT /specific_host="Homo sapiens"
 FT CDS 1..2640
 FT /db_xref="SPTREMBL:Q9WIU9"
 FT /gene="env"
 FT /product="gp160"
 FT /protein_id="CAA65373.1"
 FT
 /translation="MIVTMRVMEKXKXKLLWILCMIMALIIPCLSSNHLYATVYAGVPVW
 FT
 EDANPVLFCASDANLTSTEQHNIWASQACVPTDPTPLEYPLKNVTDNPNINKNYMBQM
 FT
 QEDIISLWEQSLKPCVQMTFLCVQMCTNINATSSNINATSSDISKDTSSSENSVKQC
 FT
 EFNITTVLKDKEKKQALFYVSDLVKTDNSTMYTLINCNSTTIKQACPKVSFEPIPIHY
 FT

CAPAGYAIFKCNTEFNGTGTCKNITVVTCTHGIKPTVSTQLILNGTSLSEKIRIMGKN
 FT
 ISDSGKNIIVTLNSSISMTCEPFGNHTVQEMKIGPMAWYSMGLEENKTNSTRAYCRYNA
 FT
 TDWEKALKQMTERYLELVNNTSNKTVTMIFNQSNDDGPEVTHLHFNCHGEFFYCNTSRM
 FT
 FNYSFSCSGTSCNSSQNNNATHNDTQIPCRLLKQVVRVSWMRGGSGLYAPPPIRGNLTCISH
 FT
 ITGMILQMDMPWNKSNTTFRPVGGDMKDIWRTELFKYKVVRVKPFSVAPTKIARPVIGT
 FT
 GTHREKRAVGLGMLFLGVLSAAGSTMGAAATALTVOAHTLIKGIQQQDNLRLAIQAAQ
 FT
 QLLRLSVWGIRQLRARLLALETLIQNQQLLNLWGCKGRLICYTSVQWNKTWTKNSNVDL
 FT
 ENIWGNLTWQEWDDQIDNISSTIYDEIQKAQVQQEQNEQKLELDEWASIWNWLDITKW
 FT
 LWYIKMAIIIVGALVGIRVVMIIILNLRNIRQGYQPLSLQTPIRHQSEAETPGRTGEGG
 FT
 GEEDRPRILIPSPQGFLLPYTDLRTIILWIYHLLSNLASGIQKAISHLGLGLWILGQKI
 FT
 ISACRICAAVTQFWLQELQNSATSLIDTLAVTVANWTDGIILGIQRIGRGIRNIPTRIR
 FT
 QGLERSLL"
 FT sig_peptide 1..87
 FT mat_peptide 88..1572
 FT /product="gp120"
 FT mat_peptide 394..468
 FT /product="V1"
 FT mat_peptide 490..600
 FT /product="V2"
 FT mat_peptide 904..1005
 FT /product="V3"
 FT mat_peptide 1183..1281
 FT /product="V4"
 FT mat_peptide 1372..1425
 FT /product="V5"
 FT mat_peptide 1573..2637
 FT /product="gp41"

XX

SQ Sequence 2640 BP; 939 A; 500 C; 582 G; 619 T; 0 other;
 atgatagtgat ctatgagagt gatggagaag aagaacaaga agttatggat cttgtgcatg
 60
 attatggctt tgataatccc atgtttgagc tctaaccatc tgtatgcaac agtatatgct
 120
 ggggtgcctg tatgggaaga tgcaaaccga gtattattct gtgcttcaga tgctaaccga
 180
 acaagcactg agcagcacia tatttgggca tcacaagcct gtgttcctac agatcccact
 240
 ccacttgagt atccattaaa aaatgtgaca gataacttca atatatggaa aaattacatg
 300
 gtagaacaaa tgcaggaaga cattattagt ttatgggaac agagtttaaa accttgtgtt
 360
 caaatgaatt tootgtgtgt acaaatgaat tgtacaaaca taagcaatgc caccagttcg
 420
 aacataagca atgccaccag ctacagatata agcaaggaca ccagttcaga gaactctgtg

480 aaacagtgtg agttfaatat aaccacagtt ctcaaggata aaaaggagaa aaaacaggct
540 ctattctatg tatcagaactt agtcaaaaca gataacagca caatgtatac attaattaat
600 tgtaactcca caaccattaa gcaagcctgc ccgaaggat catttgagcc aattccaata
660 cattattgtg ctccagcagg atatgccatc tttaagtgt acaatacaga atttaatgga
720 acaggcacat gcaagaacat tacagtagtt acttgtacac atggcatcaa gccaacagta
780 agcactcagc taatattaaa tgggacactc tctaaagaaa aaataagaat aatgggaaaa
840 aatatttcgg acagtgggaa aaatatcata gtaaccctaa attcttctat aagtatgacc
900 tgtgagagac cagggaaatca tacagtacaa gagatgaaga taggtccaat ggcctggtat
960 agcatgggccc tagaggaaaa caaaaccaac tcaaggagag cttattgcag gtataatgcc
1020 actgattggg aaaaagcctt aaaacaaatg actgaaagg atttagaact cgtaaacaaat
1080 acaagtaata aaacagtaac aatgatatto aatcaaagca atgatggaga tccagaggta
1140 acccatttgc attttaactg ccacggggaa ttcttttatt gtaaacctc tcggatgttt
1200 aattatagct ttatcatgtg tggaaaccagc tgtaatagta gccaaaataa caatgccact
1260 cacaatgaca ctacagatac ttgcaggtta aaacaagtgg taagatcatg gatgagggga
1320 gggtcgggac totatgctcc tcccatcaga ggtaacctaa catgtatata acacataact
1380 ggaatgattc taaaaatgga tatgccatgg aacaaaagca acaccacatt tagaccgta
1440 gggggagata tgaagatat atggagaact gaattattca aatacaaagt agtaagggtta
1500 aaacctttta gtgtggcacc taaaaaatt gcaaggccag tcataggcac tggcactcat
1560 agagagaaaa gagcagtagg attgggaatg ctattcttgg gggttctaag tgcagcaggc
1620 agcactatgg gcgcagcggc aacagcactg acggtacagg cccacacttt gataaagggt
1680 atagtgaac agcaggacaa cctgctaaga gcaatacagg cccagcagca attgctgagg
1740 ctatctgtat ggggtatcag acaactccga gctgcctgc tagccttaga aaccttaata
1800 cagaatcagc aactcctaaa cctgtggggc tgtaaggga ggctaactctg ctacaacctc
1860 gtacaatgga aaaaaacatg gacaaacaag tcaaatgttg acttgagaa tatttggggc
1920 aacctaacat ggcaggaatg ggatcagcag atagataaca taagtagcac catatatgat
1980 gaaatacaaa aggcacaagt acagcaagaa caaatgagc aaaagttgct ggagttagat
2040 gaatgggcct ctatttgga ttggcttgac ataactaaat ggttgtggtta tataaaaatg

2100 gcaataatca tagtāggagc actagtaggt ataagagftg tcatgataat acttaatcta
 2160 gtgagaaaca ttaggcaggg atatcaacc ctctcgttgc agaccccat ccgccatcag
 2220 tcggaagcag aaacgccagg aagaacagga gaaggaggtg gagaagaaga caggcccaga
 2280 ttgataccct cgccgaagg attcttgcca ctactgtaca cggacctcag gacaataatc
 2340 ttgtggattt accacctctt gagcaactta gcatcagga tccagaaggc gatcagccac
 2400 ctgggacttg gactgtggat cctagggcag aagataatta gtgcttgag aatttggtca
 2460 gctgtaacac aattctgggt acaagaattg caaaatagtg ctacaagtct aatagatacc
 2520 cttgcagtga cagtcgcaa ttggacagac ggcataatct tagggatata aaggatagga
 2580 agaggaattc gtaacatccc aacaagaatt agacagggtc tggaaacgaag tttactgtaa
 2640
 //

Yours sincerely

> ----- Original Message -----
 > Received: from viper.abbott.com (viper.abbott.com [130.36.44.77]) by
 > alpha1.ebi.ac.uk
 > (8.9.3/8.9.3) with SMTP id XAA336530 for <DALIB@EBI.AC.UK>; Thu, 7 Feb 2002
 > 23:48:46
 > GMT
 > From: John.Hackett@abbott.com
 > Received: from abtmr1.abbott.com (abtmr1.abbott.com [10.254.245.1]) by
 > viper.abbott.com (Switch-2.1.4/Switch-2.1.0) with ESMTTP id g17Nms514950 for
 > <DALIB@EBI.AC.UK>; Thu, 7 Feb 2002 17:48:55 -0600 (CST)
 > Received: from abtapn55.cmis.abbott.com (localhost [127.0.0.1]) by
 > abtmr1.abbott.com
 > (Switch-2.0.6/Switch-2.0.1) with ESMTTP id g17Nmhm03357 for
 > <DALIB@EBI.AC.UK>;
 > Thu, 7
 > Feb 2002 17:48:43 -0600 (CST)
 > Subject: EMBL Release date
 > To: DALIB@ebi.ac.uk
 > X-Mailer: Lotus Notes Release 5.0.5 September 22, 2000
 > Message-ID: <OF61ED78A8.AFE557B2-ON86256B59.0081F945@cmis.abbott.com>
 > Date: Thu, 7 Feb 2002 17:48:40 -0600
 > X-MIMETrack: Serialize by Router on ABTAPN55/ESVR/ABBOTT (Release 5.0.5
 > |September 22,
 > 2000) at 02/07/2002 05:47:33 PM
 > MIME-Version: 1.0
 > Content-type: text/plain; charset=us-ascii
 >
 > Hello,
 >
 > I was accessing a sequence (X96526) from the EMBL database and have a
 > question

> regarding the release of this sequence to the public. There is a line on
the
> initial text page that states the following "DT 28-August-1996 (Rel. 49,
> Created)". Is my interpretation correct that Aug 28, 1996 is the date this
> sequence was first available to the public? Thank you for your help in
> clarifying this.
>
> Best regards,
>
> John
>
> Dr. John Hackett, Jr.
> Abbott Laboratories
> D-9NG, Bldg AP20
> 100 Abbott Park Road
> Abbott Park, IL
> 60064-6015
>

(2)

#30

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John R. Hackett, Jr.
et al.

Serial No.: 08/911,824

Filed: August 15, 1997

For: Novel Antigen Constructs
Useful in the Detection and
Differentiation of Antibodies
to HIV

Attorney Docket No.: 6165.US.01

Examiner: Myron G. Hill

Group Art Unit: 1648
Certificate of Facsimile
Transmission under 37 CFR §1.8(a):
I hereby certify that this paper
(along with any paper referred to
as being attached or enclosed) is
being transmitted via facsimile,
said transmission to be completed
before midnight Eastern time on
the date shown below, addressed to
the following recipient:

Commissioner for Patents
Attn: Examiner Myron G. Hill
Group Art Unit: 1648
Washington, D.C. 20231

Recipient Telefax Number: (703) 872-9307
Kimberly A. Lorio 11-14-02
Kimberly A. Lorio

DECLARATION OF SUSHIL G. DEVARE.
PURSUANT TO 37 C.F.R. SECTION 1.131

Commissioner for Patents
Washington, D.C. 20231

Sir:


I, Sushil G. Devare, declare as follows:

1. This declaration is to establish completion of the invention in this application in the United States, at a date prior to August 28, 1996.
2. I am one of the inventors of the above-identified application.
3. I have read the Office Action mailed on May 31, 2002 in connection with the above-identified application. In the Office Action, the Examiner rejected claims 1-2 as being obvious under 35 U.S.C. Section 103(a) in view of Delaporte et al. (AIDS 1996, vol. 10 pages 903-910) (hereinafter "Delaporte").

4. To establish the date of completion of the claimed invention attached as Exhibit B is a reproduction of the notebook entries of Jennifer Lund. Ms. Lund was a Laboratory Technician who cloned and determined the entire env protein sequence of the HIV-1 Group O Isolate HAM112, which is shown in SEQ ID NO:61. Ms. Lund conducted this work at my direction and under my supervision.

5. From these documents, it can be seen that the claimed invention was made prior to August 28, 1996.

6. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.


Sushil G. Devare

11/12/02
Date